<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Pneumococcal vaccination in adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Pneumococcal vaccination in adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Pneumococcal vaccination in adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Daniel M Musher, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Maria C Rodriguez-Barradas, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Thomas M File, Jr, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Milana Bogorodskaya, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 10, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H4116609419">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pneumococcal vaccination is an important preventive health care measure that substantially reduces the burden of pneumococcal disease in vaccinated individuals and in the population. Pneumococcal vaccination is indicated for adults with risk factors for pneumococcal disease or for severe adverse outcomes should disease occur. Pneumococcal vaccination is also a routine part of infant and childhood immunization schedules worldwide.
        </p>
        <p>
         This topic will review types of pneumococcal vaccines, indications and approach to vaccine selection, safety of vaccination, and rationale for vaccination.
        </p>
        <p>
         Pneumococcal vaccination in children is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6053.html" rel="external">
          "Pneumococcal vaccination in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2139838928">
         <span class="h1">
          VACCINE TYPES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Two types of pneumococcal vaccines are available for clinical use:
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          pneumococcal polysaccharide vaccine
         </a>
         (PPSV) and pneumococcal conjugate vaccine (PCV)  (
         <a class="graphic graphic_table graphicRef87568" href="/z/d/graphic/87568.html" rel="external">
          table 1
         </a>
         ). The active components of both kinds of vaccine are capsular polysaccharides from pneumococcal serotypes that commonly cause invasive disease. (See
         <a class="medical medical_review" href="/z/d/html/7023.html" rel="external">
          "
          <i>
           Streptococcus pneumoniae
          </i>
          : Microbiology and pathogenesis of infection", section on 'Capsule'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2590188851">
         <span class="h2">
          Polysaccharide vaccines
         </span>
         <span class="headingEndMark">
          —
         </span>
         PPSV is composed of partially purified pneumococcal capsular polysaccharides. The only available formulation contains 23 pneumococcal polysaccharides (
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          PPSV23
         </a>
         ; Pneumovax or Pnu-Immune) from the 23 serotypes that were the most common cause of pneumococcal disease in adults in the 1980s  (
         <a class="graphic graphic_table graphicRef77274" href="/z/d/graphic/77274.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1551798853">
         <span class="h2">
          Conjugate vaccines
         </span>
         <span class="headingEndMark">
          —
         </span>
         PCVs consist of pneumococcal capsular polysaccharides covalently linked (conjugated) to a protein. Since these were first developed for pediatric use, earlier formulations included serotypes that caused the most disease in children. More recent formulations have selected serotypes that commonly cause disease in adults  (
         <a class="graphic graphic_table graphicRef77274" href="/z/d/graphic/77274.html" rel="external">
          table 2
         </a>
         ). Different carrier proteins have been used for conjugation, the most common being CRM197, a nontoxic, genetically altered variant of diphtheria toxin.
        </p>
        <p>
         Available PCV formulations include the 10-valent PCV (
         <a class="drug drug_general" data-topicid="17136" href="/z/d/drug information/17136.html" rel="external">
          PCV10
         </a>
         ; Synflorix), the 13-valent PCV (
         <a class="drug drug_general" data-topicid="9906" href="/z/d/drug information/9906.html" rel="external">
          PCV13
         </a>
         ; Prevnar 13), the 15-valent PCV (
         <a class="drug drug_general" data-topicid="132100" href="/z/d/drug information/132100.html" rel="external">
          PCV15
         </a>
         ; Vaxneuvance), and the 20-valent PCV (
         <a class="drug drug_general" data-topicid="131831" href="/z/d/drug information/131831.html" rel="external">
          PCV20
         </a>
         ; Prevnar 20), with the numbers indicating the number of pneumococcal capsule types included in the vaccine. The 7-valent PCV (PCV7; Prevnar 7) is an older formulation that is no longer produced.
        </p>
        <p>
         In contrast to PPSV, PCV stimulates mucosal immunity, thereby preventing nasal colonization of
         <em>
          Streptococcus pneumoniae
         </em>
         . Mucosal immunity leads to two population-level effects: (1) indirect (herd) immunity and (2) emergence of replacement strains. With widespread use of PCV in infants and children, pneumococcal transmission decreases and thus lends protection to unvaccinated individuals (including adults)  (
         <a class="graphic graphic_figure graphicRef126200" href="/z/d/graphic/126200.html" rel="external">
          figure 1
         </a>
         ). As a result, with the exception of serotypes against which the vaccines are not effective, serotypes present in PCV7 and then in
         <a class="drug drug_general" data-topicid="9906" href="/z/d/drug information/9906.html" rel="external">
          PCV13
         </a>
         have nearly disappeared from the pediatric and adult populations  (
         <a class="graphic graphic_table graphicRef77274" href="/z/d/graphic/77274.html" rel="external">
          table 2
         </a>
         ). However, as these serotypes disappear, new pneumococcal serotypes emerge to occupy the vacant ecologic niche; these are called “replacement strains.” These concepts are discussed in further detail elsewhere in the topic. (See
         <a class="local">
          'Role of indirect effect (herd immunity)'
         </a>
         below and
         <a class="local">
          'Role of replacement strains'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3135051018">
         <span class="h1">
          APPROACH TO VACCINATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The United States Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) updated its recommendation in 2022 [
         <a href="#rid1">
          1
         </a>
         ]. The approach of the authors of this topic is largely consistent with the ACIP although varies for certain patient populations. These recommendations are discussed in the sections that follow.
        </p>
        <p class="headingAnchor" id="H3531283392">
         <span class="h2">
          Indications for vaccination
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goal of vaccination in adults is to prevent invasive pneumococcal disease (IPD; eg, bacteremic pneumonia, meningitis) and nonbacteremic pneumonia. In agreement with the ACIP [
         <a href="#rid1">
          1
         </a>
         ], we recommend pneumococcal vaccination for  (
         <a class="graphic graphic_table graphicRef86782" href="/z/d/graphic/86782.html" rel="external">
          table 3
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         All adults ≥65 years of age
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adults aged 19 to 64 years with:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Predisposing chronic medical conditions (eg, chronic lung disease, chronic liver disease, diabetes mellitus)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Increased risk of meningitis (eg, cochlear implant, cerebrospinal fluid [CSF] leak)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Immunocompromising conditions (eg, human immunodeficiency virus [HIV] infection, hematologic malignancies) and other conditions associated with altered immunocompetence (functional or anatomic asplenia, chronic renal disease, and nephrotic syndrome)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Functional or anatomic asplenia
        </p>
        <p>
        </p>
        <p>
         In addition to the indications outlined by the ACIP, we also recommend pneumococcal vaccination for those with prior history of IPD.
        </p>
        <p>
         In situations where it is unclear whether pneumococcal vaccination is indicated or not, we choose to vaccinate because the benefits of the vaccine outweigh the minimal risks.
        </p>
        <p>
         These populations are at increased risk of developing IPD and/or are at higher risk of morbidity and mortality from IPD. In 2018, approximately 43 percent of IPD occurred in those over the age of 65 and another 48 percent in adults &lt;65 years of age with predisposing conditions  (
         <a class="graphic graphic_figure graphicRef138890" href="/z/d/graphic/138890.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ]. While there is evidence that many patients with immunocompromising conditions such as lymphoma or multiple myeloma are unlikely to develop antibody following vaccination with pneumococcal conjugate vaccines (PCV) or
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          pneumococcal polysaccharide vaccine
         </a>
         (PPSV), the potential benefits of even suboptimal responses greatly outweigh the risks and the cost is regarded as appropriate for the benefit received [
         <a href="#rid3">
          3,4
         </a>
         ]. (See
         <a class="local">
          'Rationale for vaccination'
         </a>
         below.)
        </p>
        <p>
         Vaccination is not recommended for healthy adults less than 65 years of age. Although the risk for pneumococcal disease starts to increase at age 50  (
         <a class="graphic graphic_figure graphicRef138890" href="/z/d/graphic/138890.html" rel="external">
          figure 2
         </a>
         ), analyses have suggested initiating vaccination at that age would not be cost-effective; thus, the ACIP did not lower the recommended age for vaccination in healthy adults [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1725092960">
         <span class="h2">
          Vaccine selection
         </span>
        </p>
        <p class="headingAnchor" id="H2761318827">
         <span class="h3">
          Approach to healthy older adults and those with predisposing medical conditions
         </span>
         <span class="headingEndMark">
          —
         </span>
         The ACIP recommends the 20-valent PCV (
         <a class="drug drug_general" data-topicid="131831" href="/z/d/drug information/131831.html" rel="external">
          PCV20
         </a>
         ) alone or the 15-valent PCV (
         <a class="drug drug_general" data-topicid="132100" href="/z/d/drug information/132100.html" rel="external">
          PCV15
         </a>
         ) followed by the 23-valent PPSV (
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          PPSV23
         </a>
         ) for all adults with indications for vaccination  (
         <a class="graphic graphic_table graphicRef86782" href="/z/d/graphic/86782.html" rel="external">
          table 3
         </a>
         ). For most adults, including healthy older adults, those with predisposing medical conditions, and those with a history of IPD, we prefer to administer PCV20, when available, due to the simplicity and lower cost of a single-dose vaccine. Comparative efficacy of these two approaches is unknown.
        </p>
        <p>
         If
         <a class="drug drug_general" data-topicid="131831" href="/z/d/drug information/131831.html" rel="external">
          PCV20
         </a>
         is not available,
         <a class="drug drug_general" data-topicid="132100" href="/z/d/drug information/132100.html" rel="external">
          PCV15
         </a>
         followed by
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          PPSV23
         </a>
         is a recommended alternative. If PCV15 is administered, PPSV23 should be administered one year after PCV15 to provide immunity against an increased number of pneumococcal serotypes. When the series PCV15 followed by PPSV23 is completed, protection is offered to an additional three serotypes compared with the single PCV20 approach. Although it is hypothesized that the immunogenicity of PPSV is boosted by prior administration of PCV, this booster effect has not been convincingly demonstrated [
         <a href="#rid6">
          6,7
         </a>
         ].
        </p>
        <p>
         Some experts may prefer
         <a class="drug drug_general" data-topicid="132100" href="/z/d/drug information/132100.html" rel="external">
          PCV15
         </a>
         followed by
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          PPSV23
         </a>
         to
         <a class="drug drug_general" data-topicid="131831" href="/z/d/drug information/131831.html" rel="external">
          PCV20
         </a>
         alone based on indirect preliminary data suggesting PCV15 may be more immunogenic than PCV20 [
         <a href="#rid8">
          8
         </a>
         ] (but the data only demonstrate immunogenicity for the first 30 days post-vaccination) and because PCV15 has been studied in immunocompromised individuals (eg, patients with HIV) [
         <a href="#rid8">
          8,9
         </a>
         ]. No study to date has directly compared PCV15 and PCV20, and the clinical significance of higher antibody levels 30 days after vaccination is unknown.
        </p>
        <p class="headingAnchor" id="H3704960110">
         <span class="h3">
          Approach to individuals at highest risk of pneumococcal disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         For immunocompromised individuals (eg, transplant recipients, persons with HIV) and those at increased risk for meningitis (eg, cochlear implant, CSF leak), the authors prefer to administer
         <a class="drug drug_general" data-topicid="131831" href="/z/d/drug information/131831.html" rel="external">
          PCV20
         </a>
         followed by
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          PPSV23
         </a>
         ≥8 weeks later. This recommendation differs from the ACIP and other experts’ recommendations to administer PCV20 alone (or
         <a class="drug drug_general" data-topicid="132100" href="/z/d/drug information/132100.html" rel="external">
          PCV15
         </a>
         followed by PPSV23) in these populations. The authors administer the PPSV23 in addition to PCV20 in these individuals to provide protection against serotypes present in PPSV23 that are absent from PCV20. Although PCV20 covers the majority of the serotypes implicated in IPD, there are three relatively common serotypes (9N, 20, 17F) included in PPSV23 that are not included in PCV20  (
         <a class="graphic graphic_figure graphicRef138710" href="/z/d/graphic/138710.html" rel="external">
          figure 3
         </a>
         ) [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         Additional detail on vaccine efficacy and timing in specific immunocompromised patients is provided separately. (See
         <a class="local">
          'Rationale for vaccination'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/85526.html" rel="external">
          "Pneumococcal immunization in adults with HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/103773.html" rel="external">
          "Immunizations in autoimmune inflammatory rheumatic disease in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3899.html" rel="external">
          "Immunizations in adults with cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3892.html" rel="external">
          "Immunizations in solid organ transplant candidates and recipients"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3882.html" rel="external">
          "Immunizations in hematopoietic cell transplant candidates and recipients"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2658793051">
         <span class="h3">
          Approach to recipients of prior pneumococcal vaccines
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to complete the pneumococcal vaccination series for individuals who have already received pneumococcal vaccination depends on age and the specific vaccine they received  (
         <a class="graphic graphic_table graphicRef143140" href="/z/d/graphic/143140.html" rel="external">
          table 4
         </a>
         and
         <a class="graphic graphic_table graphicRef143139" href="/z/d/graphic/143139.html" rel="external">
          table 5
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pneumococcal polysaccharide vaccine
         </strong>
         <strong>
          only
         </strong>
         − Adults who have only received the
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          PPSV23
         </a>
         vaccine should receive
         <a class="drug drug_general" data-topicid="131831" href="/z/d/drug information/131831.html" rel="external">
          PCV20
         </a>
         (or
         <a class="drug drug_general" data-topicid="132100" href="/z/d/drug information/132100.html" rel="external">
          PCV15
         </a>
         if PCV20 is not available) at least a year after PPSV23 [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         10-valent pneumococcal conjugate vaccine
         <strong>
          or
         </strong>
         13-valent pneumococcal conjugate vaccine
         <strong>
          only
         </strong>
         − Adults who have only received
         <a class="drug drug_general" data-topicid="17136" href="/z/d/drug information/17136.html" rel="external">
          PCV10
         </a>
         or
         <a class="drug drug_general" data-topicid="9906" href="/z/d/drug information/9906.html" rel="external">
          PCV13
         </a>
         should receive
         <a class="drug drug_general" data-topicid="131831" href="/z/d/drug information/131831.html" rel="external">
          PCV20
         </a>
         (or
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          PPSV23
         </a>
         if PCV20 is not available) typically at least one year after receipt of PCV10 or PCV13 [
         <a href="#rid11">
          11
         </a>
         ]. However, for those at highest risk for pneumococcal disease (immunocompromised individuals, presence of cochlear implant or CSF leak) receiving PPSV23, a shorter interval of at least 8 weeks after receipt of PCV10 or PCV13 may be used. (See
         <a class="local">
          'Approach to individuals at highest risk of pneumococcal disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Both
         </strong>
         10-valent pneumococcal conjugate vaccine
         <strong>
          /
         </strong>
         13-valent pneumococcal conjugate vaccine
         <strong>
          and
         </strong>
         <strong>
          Pneumococcal polysaccharide vaccine
         </strong>
         <strong>
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Adults ≥65 years of age:
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Those who received both the
         <a class="drug drug_general" data-topicid="17136" href="/z/d/drug information/17136.html" rel="external">
          PCV10
         </a>
         /
         <a class="drug drug_general" data-topicid="9906" href="/z/d/drug information/9906.html" rel="external">
          PCV13
         </a>
         and
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          PPSV23
         </a>
         prior to age 65 years should receive
         <a class="drug drug_general" data-topicid="131831" href="/z/d/drug information/131831.html" rel="external">
          PCV20
         </a>
         or PPSV23 (if PCV20 is not available) ≥5 years after their last pneumococcal vaccine dose [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Those who received
         <a class="drug drug_general" data-topicid="17136" href="/z/d/drug information/17136.html" rel="external">
          PCV10
         </a>
         /
         <a class="drug drug_general" data-topicid="9906" href="/z/d/drug information/9906.html" rel="external">
          PCV13
         </a>
         at any age and
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          PPSV23
         </a>
         at ≥65 years of age, the ACIP advises shared decision-making between clinician and patient regarding whether to administer
         <a class="drug drug_general" data-topicid="131831" href="/z/d/drug information/131831.html" rel="external">
          PCV20
         </a>
         ≥5 years after their last pneumococcal vaccine [
         <a href="#rid11">
          11
         </a>
         ]. The authors of this topic prefer to administer PCV20 (or PPSV23 if PCV20 is not available) ≥5 years after the patient’s last pneumococcal vaccine since the benefits generally outweigh the minimal risks of an adverse vaccine reaction.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Adults aged 19 to 64:
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          For patients with chronic conditions
         </strong>
         , the ACIP does not recommend further vaccination until age 65 [
         <a href="#rid11">
          11
         </a>
         ]. The authors of this topic prefer to give
         <a class="drug drug_general" data-topicid="131831" href="/z/d/drug information/131831.html" rel="external">
          PCV20
         </a>
         ≥5 years after last pneumococcal vaccine dose. If PCV20 is not available, the authors administer
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          PPSV23
         </a>
         after ≥1 year has passed since last
         <a class="drug drug_general" data-topicid="17136" href="/z/d/drug information/17136.html" rel="external">
          PCV10
         </a>
         /
         <a class="drug drug_general" data-topicid="9906" href="/z/d/drug information/9906.html" rel="external">
          PCV13
         </a>
         dose and ≥5 years have passed since last PPSV23.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Patients at increased risk of meningitis (eg, CSF leak, cochlear implant)
         </strong>
         should receive
         <a class="drug drug_general" data-topicid="131831" href="/z/d/drug information/131831.html" rel="external">
          PCV20
         </a>
         ≥5 years after last pneumococcal vaccine dose [
         <a href="#rid11">
          11
         </a>
         ]. If PCV20 is not available, the ACIP does not recommend further vaccination until age 65. The authors of this topic prefer to give
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          PPSV23
         </a>
         ≥5 years after last pneumococcal vaccine dose if PCV20 is not available.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Immunocompromised patients
         </strong>
         should receive
         <a class="drug drug_general" data-topicid="131831" href="/z/d/drug information/131831.html" rel="external">
          PCV20
         </a>
         ≥5 years after their last pneumococcal vaccine dose [
         <a href="#rid11">
          11
         </a>
         ]. If PCV20 is not available,
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          PPSV23
         </a>
         administered ≥8 weeks after last
         <a class="drug drug_general" data-topicid="17136" href="/z/d/drug information/17136.html" rel="external">
          PCV10
         </a>
         or
         <a class="drug drug_general" data-topicid="9906" href="/z/d/drug information/9906.html" rel="external">
          PCV13
         </a>
         dose and ≥5 years after last PPSV23 dose is a reasonable alternative. The ACIP recommends a total of two PPSV23 vaccine doses (≥5 years apart) for immunocompromised patients and to review vaccination recommendations once the patient turns 65 years old. Those who have received PCV10/PCV13 and two doses of PPSV23 can receive PCV20 five years after their last pneumococcal vaccination, if available.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2174985709">
         <span class="h2">
          Revaccination
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to revaccination varies among experts and clinical practice guidelines. The ACIP does not recommend additional doses of pneumococcal vaccines beyond those discussed above. (See
         <a class="local">
          'Vaccine selection'
         </a>
         above.) In contrast, the authors of this topic offer repeat vaccination with
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          PPSV23
         </a>
         every 5 to 10 years to all adults who received PPSV23 as part of their vaccine series (eg,
         <a class="drug drug_general" data-topicid="9906" href="/z/d/drug information/9906.html" rel="external">
          PCV13
         </a>
         and PPSV23,
         <a class="drug drug_general" data-topicid="132100" href="/z/d/drug information/132100.html" rel="external">
          PCV15
         </a>
         and PPSV23, or
         <a class="drug drug_general" data-topicid="131831" href="/z/d/drug information/131831.html" rel="external">
          PCV20
         </a>
         and PPSV23 for patients at higher risk of invasive pneumococcal disease). While this differs from the CDC ACIP recommendation, the authors believe the potential benefit of repeat revaccination with PPSV23 every 5 to 10 years greatly outweighs the risks.
        </p>
        <p>
         The authors' recommendation for revaccination every 5 to 10 years is based on in vitro studies that show waning of antibody and field studies that show waning effectiveness after vaccination with
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          PPSV23
         </a>
         [
         <a href="#rid12">
          12-14
         </a>
         ]. Although data on duration of antibody and effectiveness after receipt of PCV are not available beyond five years, any difference in opsonophagocytic effect between PPSV23 and
         <a class="drug drug_general" data-topicid="9906" href="/z/d/drug information/9906.html" rel="external">
          PCV13
         </a>
         is no longer detectable after 12 months [
         <a href="#rid15">
          15
         </a>
         ]. The authors suspect that no pneumococcal vaccine will provide lifetime protection and believe the potential benefits of repeat revaccination with PPSV23 every 5 to 10 years greatly outweigh the risks. Since there are no data on revaccination with PCV, the authors only revaccinate with PPSV23.
        </p>
        <p class="headingAnchor" id="H3961285258">
         <span class="h1">
          VACCINE ADMINISTRATION
         </span>
        </p>
        <p class="headingAnchor" id="H2661724194">
         <span class="h2">
          Dose and route
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pneumococcal vaccines are administered intramuscularly as a 0.5 mL dose.
        </p>
        <p class="headingAnchor" id="H1531371084">
         <span class="h2">
          Administration with other vaccines
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pneumococcal vaccines generally may be given concomitantly with other nonpneumococcal vaccines [
         <a href="#rid16">
          16-18
         </a>
         ]. When more than one vaccine is given, they should be administered with different syringes and at different injection sites.
        </p>
        <p>
         Concurrent administration of the 23-valent
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          pneumococcal polysaccharide vaccine
         </a>
         (PPSV23) with the influenza vaccine is safe and does not alter the effectiveness of either vaccine [
         <a href="#rid19">
          19
         </a>
         ]. Concomitant administration of the 20-valent PCV (
         <a class="drug drug_general" data-topicid="131831" href="/z/d/drug information/131831.html" rel="external">
          PCV20
         </a>
         ) with adjuvanted quadrivalent influenza vaccine (Fluad) [
         <a href="#rid1">
          1
         </a>
         ] as well as BNT162b2 SARS-CoV-2 vaccine [
         <a href="#rid20">
          20
         </a>
         ] have also been demonstrated to be immunogenic and safe. The
         <a class="drug drug_general" data-topicid="132100" href="/z/d/drug information/132100.html" rel="external">
          15-valent pneumococcal conjugate vaccine
         </a>
         (PCV15) has been demonstrated to be safe and immunogenic when given with the quadrivalent influenza vaccine (Fluarix) [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2854983068">
         <span class="h1">
          SAFETY
         </span>
        </p>
        <p class="headingAnchor" id="H1056283011">
         <span class="h2">
          Adverse effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         The immune response to pneumococcal vaccination can elicit a clinically apparent inflammatory response at the injection site and systemically. While most adverse effects associated with vaccination are not severe and are self-limited, all should be reported. In the United States, suspected adverse events should be reported to the Vaccine Adverse Event Reporting System (VAERS). VAERS can be contacted via the
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fvaers.hhs.gov%2Findex&amp;token=dJuRidyjQYZxq9fkueW6qyWTvn%2Fp9jDJLlDYcIYjX1yIn9pmTuN0f%2BLI7X4NwNtw&amp;TOPIC_ID=7021" target="_blank">
          VAERS website
         </a>
         or by telephone at 1-800-822-7967.
        </p>
        <p class="headingAnchor" id="H2392533858">
         <span class="h3">
          Injection site reactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Injection site reactions are the most common adverse effects associated with pneumococcal vaccination in adults [
         <a href="#rid16">
          16-18
         </a>
         ]. For the 23-valent
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          pneumococcal polysaccharide vaccine
         </a>
         (PPSV23), pain and tenderness at the injection site occur in over half of vaccinees, swelling and/or induration in approximately 20 percent, and redness in approximately 15 percent [
         <a href="#rid16">
          16
         </a>
         ]. Rates are similar for pneumococcal conjugate vaccines (PCV) [
         <a href="#rid17">
          17,18
         </a>
         ]. In some, these symptoms limit arm movement.
        </p>
        <p>
         Injection site reactions usually resolve spontaneously over three to four days. Nonsteroidal anti-inflammatory drugs and warm compresses can help relieve pain.
        </p>
        <p class="headingAnchor" id="H2887522407">
         <span class="h3">
          Other adverse effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systemic symptoms (eg, fever, chills, fatigue, headache, myalgias, arthralgias) can also occur following vaccination [
         <a href="#rid16">
          16-18
         </a>
         ]. While fever (temperature ≥38°C) occurs in less than 5 percent, other systemic symptoms occur frequently but are usually mild. Like injection site reactions, systemic symptoms following vaccination are self-limited.
        </p>
        <p class="headingAnchor" id="H2521269758">
         <span class="h2">
          Contraindications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vaccination is contraindicated for patients who have a history of severe allergic reactions (eg, anaphylaxis) to either pneumococcal vaccine or any of its components (eg, diphtheria toxoid for PCV).
        </p>
        <p class="headingAnchor" id="H667208892">
         <span class="h1">
          RATIONALE FOR VACCINATION
         </span>
        </p>
        <p class="headingAnchor" id="H18286342">
         <span class="h2">
          Burden of disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          S. pneumoniae
         </em>
         is the leading bacterial cause of pneumonia worldwide [
         <a href="#rid21">
          21
         </a>
         ]. Other manifestations of pneumococcal infection include meningitis, bacteremia of undetermined source, acute purulent sinusitis, and otitis media. These pneumococcal infections cause substantial morbidity and mortality [
         <a href="#rid22">
          22
         </a>
         ]. Further discussion of the epidemiology of invasive pneumococcal disease (IPD) is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3168.html" rel="external">
          "Invasive pneumococcal (Streptococcus pneumoniae) infections and bacteremia in adults", section on 'Epidemiology'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2441322334">
         <span class="h2">
          Immunogenicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both the 23-valent
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          pneumococcal polysaccharide vaccine
         </a>
         (PPSV23) and pneumococcal conjugate vaccines (PCV) are immunogenic in adults. Numerous studies have compared responses with polysaccharide and conjugate vaccines and demonstrated no consistent differences in immunogenicity between the two vaccine types.
        </p>
        <p>
         The response to pneumococcal vaccine in adults is measured by the rise in antibody levels and/or serum opsonic (phagocytic) activity after vaccine administration. Antibody responses may be reported as mean immunoglobulin (Ig)G levels or opsonophagocytic titers (the dilution at which serum shows an opsonizing [phagocytic] effect). Opsonophagocytic titers are thought to be a better indication of protective immunity because IgG generated by older and more frail adults may be less effective in opsonizing pneumococci for phagocytosis compared with healthy young adults [
         <a href="#rid23">
          23,24
         </a>
         ].
        </p>
        <p>
         Mean antibody levels to pneumococcal polysaccharides increase after use of any of the vaccines described above. In large groups of adults, mean IgG levels remain higher than at baseline 5 and 10 years after
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          PPSV23
         </a>
         , although vaccine efficacy wanes with time [
         <a href="#rid13">
          13,14
         </a>
         ]. Antibody levels remain elevated for up to two years after vaccination with PCV; to our knowledge, longer-range studies have not been reported for PCV.
        </p>
        <p>
         Numerous studies have compared responses with polysaccharide and conjugate vaccines one to two months after vaccination of healthy adults [
         <a href="#rid6">
          6,7,15,25,26
         </a>
         ]. IgG levels and opsonic activity are often, but not consistently, slightly higher to some but not all polysaccharides after PCV [
         <a href="#rid6">
          6,15
         </a>
         ]. One study reported distinctly higher levels of opsonic activity one month after PCV when compared with PPSV, but these differences had disappeared one year after vaccination [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         In frail and elderly subjects, studies have also not shown a difference in immunogenic response between the two vaccine types [
         <a href="#rid7">
          7,25
         </a>
         ]. One study found that six months after vaccination, IgG levels and opsonophagocytic titers were higher to 2 of 10 polysaccharides in PCV recipients and higher to two other polysaccharides in PPSV recipients [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         In immunocompromised patients, limited data suggest PCV to be more immunogenic compared with
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          PPSV23
         </a>
         . As an example, in one randomized study of 128 patients with treatment-naïve chronic lymphocytic leukemia, better opsonic activity for 4 out of 10 serotypes was seen six months postvaccination in those who received the 13-valent PCV (
         <a class="drug drug_general" data-topicid="9906" href="/z/d/drug information/9906.html" rel="external">
          PCV13
         </a>
         ) compared with PPSV23 [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
         Data on the 15-valent PCV (
         <a class="drug drug_general" data-topicid="132100" href="/z/d/drug information/132100.html" rel="external">
          PCV15
         </a>
         ) and the 20-valent PCV (
         <a class="drug drug_general" data-topicid="131831" href="/z/d/drug information/131831.html" rel="external">
          PCV20
         </a>
         ) immunogenicity are limited. Antibody levels one month postvaccination were similar for PCV15 [
         <a href="#rid27">
          27,28
         </a>
         ] or PCV20 [
         <a href="#rid29">
          29
         </a>
         ] compared with
         <a class="drug drug_general" data-topicid="9906" href="/z/d/drug information/9906.html" rel="external">
          PCV13
         </a>
         for the serotypes common to all three PCVs. Similarly, antibody levels were similar to serotypes common to PCV20 and
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          PPSV23
         </a>
         that are absent from PCV13 among PCV20 and PPSV23 recipients [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2336553923">
         <span class="h2">
          Vaccine efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vaccine efficacy is assessed by conducting randomized vaccine trials and evaluating for differences in disease incidence.
        </p>
        <p class="headingAnchor" id="H1192804593">
         <span class="h3">
          Polysaccharide vaccine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          PPSV23
         </a>
         has been shown to be effective in preventing IPD and pneumococcal pneumonia [
         <a href="#rid12">
          12,31-37
         </a>
         ]. In a meta-analysis of 18 randomized trials evaluating over 64,500 individuals, PPSV23 was found to reduce the risk of IPD (14 versus 140 events; odds ratio [OR] 0.18, 95% CI 0.10-0.31), as well as invasive (15 versus 60 events; OR 0.26, 95% CI 0.15-0.46) and noninvasive pneumococcal pneumonia (100 versus 276 events; OR 0.46, 95% CI 0.25-0.84) [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         We regard the above results as having been valid at the time these studies were carried out. However, the degree of protection provided by PPSV has been debated among experts and has varied among studies. For example, some suggest that PPSV protects against invasive (ie, bacteremic pneumococcal pneumonia) but not against non-IPD [
         <a href="#rid12">
          12,31-36,39-43
         </a>
         ]; others have failed to demonstrate efficacy for preventing either invasive or noninvasive disease [
         <a href="#rid43">
          43-47
         </a>
         ] or for reducing mortality [
         <a href="#rid37">
          37,38
         </a>
         ]. Possible reasons for the conflicting results include the low frequency of the outcomes being assessed (leading to a small number of events in studies), difficulties in accurately diagnosing nonbacteremic pneumococcal pneumonia, and use of nonvalidated diagnostic tests (which may lead to false-positive results and reduce the apparent efficacy of the vaccine). As might be expected, studies with more specific endpoints (eg, IPD caused by specific vaccine serotypes) have been more likely to demonstrate vaccine efficacy than those with less specific endpoints (eg, all-cause pneumonia, all-cause mortality) [
         <a href="#rid39">
          39
         </a>
         ]. The vaccine efficacy of
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          PPSV23
         </a>
         in more recent studies of IPD has ranged from 14 to 47 percent. It is unclear why efficacy appears to be lower than it was in the past. Some studies included a substantial proportion of immunocompromised patients [
         <a href="#rid48">
          48,49
         </a>
         ], others included subjects &gt;75 years of age [
         <a href="#rid50">
          50
         </a>
         ], and others included patients who were many years past vaccination [
         <a href="#rid51">
          51,52
         </a>
         ]. For example, in one study the mean time from vaccination to pneumococcal infection was 10.3 years [
         <a href="#rid52">
          52
         </a>
         ]. The time from vaccination to pneumococcal infection is important, as immunity wanes over time with PPSV23. In one study of adults ≥75 years of age, vaccine effectiveness declined from 74 percent within the first year after receiving PPSV23 to 15 percent five years postvaccination [
         <a href="#rid50">
          50
         </a>
         ]. In another study, PPSV23 vaccine effectiveness decreased from 41 percent within two years of vaccination to 23 percent five years after vaccination [
         <a href="#rid48">
          48
         </a>
         ]. Similar data are not available for PCV.
        </p>
        <p class="headingAnchor" id="H18831544">
         <span class="h3">
          Conjugate vaccines
         </span>
         <span class="headingEndMark">
          —
         </span>
         PCV are effective against IPD and nonbacteremic pneumonia. In a large, randomized trial (CAPiTA) of over 84,000 Dutch adults ≥65 years old who received either
         <a class="drug drug_general" data-topicid="9906" href="/z/d/drug information/9906.html" rel="external">
          PCV13
         </a>
         or placebo, PCV13 showed efficacy of 75 percent (95% CI 41-91 percent) against vaccine-type IPD, 46 percent (95% CI 22-63 percent) against vaccine-type pneumococcal pneumonia, and 45 percent (95% CI 14-65 percent) against vaccine-type nonbacteremic pneumococcal pneumonia [
         <a href="#rid53">
          53
         </a>
         ]. Efficacy persisted for the duration of the trial (mean follow-up was four years).
        </p>
        <p>
         The CAPiTA trial did not compare
         <a class="drug drug_general" data-topicid="9906" href="/z/d/drug information/9906.html" rel="external">
          PCV13
         </a>
         with
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          PPSV23
         </a>
         arm, hence, its results cannot be extrapolated to make conclusions on the improved efficacy of PCV over PPSV23 in adults. Additionally, the context for CAPiTA needs to be outlined. At the time this study was begun in Holland: (1) almost no adults had previously received any pneumococcal vaccine; (2) use of PCV in children was just beginning, meaning that it was a vaccine-naïve population; and (3) the investigators excluded patients who had any immunocompromising condition or medication. Further, they excluded anyone who developed an immunocompromising condition during the trial from the final data analysis (eg, patients who were later found to have a hematologic malignancy, patients who started glucocorticoids). When results in patients who became immunocompromised after having been vaccinated were separately analyzed, no benefit of PCV was demonstrated (22 cases of pneumococcal disease in vaccine recipients versus 24 cases in placebo recipients).
        </p>
        <p>
         Another important study comparing the 7-valent PCV (PCV7) with placebo in Malawi showed efficacy of PCV7 against pneumonia over a five-year follow-up period in adults (many with acquired immunodeficiency syndrome [AIDS]) who had previously had pneumococcal pneumonia [
         <a href="#rid54">
          54
         </a>
         ]. A more recent study reported around 70 percent efficacy for
         <a class="drug drug_general" data-topicid="9906" href="/z/d/drug information/9906.html" rel="external">
          PCV13
         </a>
         against community-acquired pneumonia [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H205913649">
         <span class="h2">
          Vaccine coverage against circulating serotypes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serotypes that cause pneumococcal disease continue to change as new conjugate vaccines are added to children’s immunization programs. This is due to a reduction in PCV-serotype nasopharyngeal colonization rates in children, leading to herd immunity and reduced incidence of disease caused by those serotypes among the entire population (including adults). Consequently, as vaccine serotypes disappear from the community, other nonvaccine serotypes take their place. These two population-level phenomena (indirect effect [or herd immunity] and emergence of replacement strains) are discussed below.
        </p>
        <p>
         In a study of isolates from persons with IPD in 2017, 31.2 percent were non-PCV13 serotypes covered by
         <a class="drug drug_general" data-topicid="131831" href="/z/d/drug information/131831.html" rel="external">
          PCV20
         </a>
         ; however, 14 percent were non-PCV20 serotypes. In 2018 to 2019, of the serotypes recovered from adults &gt;18 years with IPD, 27 to 30 percent were included in
         <a class="drug drug_general" data-topicid="9906" href="/z/d/drug information/9906.html" rel="external">
          PCV13
         </a>
         . An additional 13 to 15 percent in
         <a class="drug drug_general" data-topicid="132100" href="/z/d/drug information/132100.html" rel="external">
          PCV15
         </a>
         , 27 to 28 percent in PCV20, and 35 to 43 percent in
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          PPSV23
         </a>
         [
         <a href="#rid1">
          1
         </a>
         ]. In a prospective study of 1482 adults with pneumococcal pneumonia, 37 percent were due to PCV13 serotypes and an additional 27 percent and 8 percent were due to serotypes unique to PCV20 and PPSV23, respectively  (
         <a class="graphic graphic_figure graphicRef138710" href="/z/d/graphic/138710.html" rel="external">
          figure 3
         </a>
         ) [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
         These data help to explain why we prefer
         <a class="drug drug_general" data-topicid="131831" href="/z/d/drug information/131831.html" rel="external">
          PCV20
         </a>
         to
         <a class="drug drug_general" data-topicid="132100" href="/z/d/drug information/132100.html" rel="external">
          PCV15
         </a>
         and why we recommend
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          PPSV23
         </a>
         after PCV20 for those persons at highest risk of pneumococcal infection. It is worth noting that, while all of these vaccines contain type 3 and type 19A capsular polysaccharide, for unknown reasons they have only a minimal protective effect and these two types continue to cause nearly 20 percent of invasive pneumococcal infection.
        </p>
        <p class="headingAnchor" id="H3167355239">
         <span class="h3">
          Role of indirect effect (herd immunity)
         </span>
         <span class="headingEndMark">
          —
         </span>
         The PCV owes its success to its ability directly to prevent infection in vaccinated individuals and indirectly to reduce contagion in the population by reducing nasopharyngeal colonization rates (termed "indirect effect" or "herd immunity"). As a result of herd or indirect immunity, the epidemiology of pneumococcal disease and the effectiveness of PCV in adults are all affected by vaccination programs that are in place for children. This important factor needs to be considered in evaluating recommendations for administering PCV to adults. (See
         <a class="local">
          'Vaccine selection'
         </a>
         above.)
        </p>
        <p>
         When
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          PPSV23
         </a>
         was first marketed, it contained capsular polysaccharides from serotypes that caused nearly 90 percent of all pneumococcal disease in adults. This number has declined to about 40 percent following the introduction of PCV.
        </p>
        <p>
         When the first PCV appeared (PCV7 [no longer marketed]) it contained capsular polysaccharides from serotypes that caused about 50 percent of all pneumococcal disease in adults. Widespread use of this vaccine in infants and toddlers eliminated carriage of these strains in vaccine recipients which was followed by a near-disappearance of these strains in adults  (
         <a class="graphic graphic_figure graphicRef64834" href="/z/d/graphic/64834.html" rel="external">
          figure 4
         </a>
         ) [
         <a href="#rid56">
          56-60
         </a>
         ], illustrating the indirect effect of this vaccine. The same result has followed the use of
         <a class="drug drug_general" data-topicid="9906" href="/z/d/drug information/9906.html" rel="external">
          PCV13
         </a>
         , except for certain serotypes (such as type 3) against which the vaccine, for undetermined reasons, provides little protection. Thus, by eight years after introduction of PCV13 for children, serotypes covered by PCV13 accounted for no more than 30 percent of IPD in adults  (
         <a class="graphic graphic_figure graphicRef126200" href="/z/d/graphic/126200.html" rel="external">
          figure 1
         </a>
         ). Because the reduction of PCV13 strain-related illness in adults is primarily attributable to the overall reduction in circulation of PCV13 strains due to widespread vaccination in children [
         <a href="#rid6">
          6,61-63
         </a>
         ], the rationale for vaccinating any immunocompetent older adults with a conjugate vaccine becomes less clear. We suspect the same phenomenon will be seen after
         <a class="drug drug_general" data-topicid="131831" href="/z/d/drug information/131831.html" rel="external">
          PCV20
         </a>
         becomes widely used in the pediatric population.
        </p>
        <p class="headingAnchor" id="H3465904163">
         <span class="h3">
          Role of replacement strains
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vaccination with PCV and the subsequent reduction in nasal carriage of PCV serotypes appears to create an ecologic niche for nonvaccine serotypes, mostly among children [
         <a href="#rid39">
          39
         </a>
         ]. The widespread use of pneumococcal conjugate vaccines has caused the emergence of "replacement strains," a term used to describe nonvaccine pneumococcal serotypes that have appeared as colonizers of the nasopharynx and as a cause of pneumococcal disease [
         <a href="#rid64">
          64
         </a>
         ]. As an example,
         <em>
          S. pneumoniae
         </em>
         type 19A (not included in PCV7) emerged as the most common cause of pneumococcal disease in children and adults a few years after universal vaccination with PCV7 began in the United States  (
         <a class="graphic graphic_figure graphicRef64834" href="/z/d/graphic/64834.html" rel="external">
          figure 4
         </a>
         ) [
         <a href="#rid59">
          59,65
         </a>
         ]. Several other serotypes have greatly increased in prevalence since the introduction of
         <a class="drug drug_general" data-topicid="9906" href="/z/d/drug information/9906.html" rel="external">
          PCV13
         </a>
         [
         <a href="#rid10">
          10,66,67
         </a>
         ].
        </p>
        <p>
         The epidemiologic problem that results is that the use of vaccines that contain protein-conjugated capsular polysaccharides creates a moving target and other approaches to vaccination need to be sought. (See
         <a class="local">
          'Investigational approaches'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3665413226">
         <span class="h1">
          COST-EFFECTIVENESS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Administration of the
         <a class="drug drug_general" data-topicid="131831" href="/z/d/drug information/131831.html" rel="external">
          20-valent pneumococcal conjugate vaccine
         </a>
         (PCV20) alone or the 15-valent PCV (
         <a class="drug drug_general" data-topicid="132100" href="/z/d/drug information/132100.html" rel="external">
          PCV15
         </a>
         ) in series with the 23-valent
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          pneumococcal polysaccharide vaccine
         </a>
         (PPSV23) to all adults ≥65 years appears to be cost-effective when compared with the prior recommendations [
         <a href="#rid1">
          1
         </a>
         ]. For PCV20 alone for all adults aged ≥65 years, cost-effectiveness estimates ranged from cost-saving to USD $39,000 per quality-adjusted life-year (QALY) gained. For PCV15 in series with PPSV23 for all adults aged ≥65 years, estimates ranged from cost-saving to $282,000 per QALY gained. Cost estimates of policy options for adults aged 19 to 64 years with certain underlying medical conditions ranged from USD $11,000 to USD $292,000 per QALY gained for PCV20 and from USD $250,000 to USD $656,000 for PCV15 in series with PPSV23. Although evaluated by different models, PCV20 alone was more cost-effective than PCV15 followed by PPSV23. Models included indirect effect and waning of effectiveness. The expected decline in disease due to PCV20 types in adults once this conjugate vaccine is recommended for widespread use in infants and toddlers will almost certainly render the use of PCV20 in adults less cost-efficient. (See
         <a class="local">
          'Role of indirect effect (herd immunity)'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2539768208">
         <span class="h1">
          INVESTIGATIONAL APPROACHES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data suggest that the best approach for new vaccines might be to target virulence factors other than the pneumococcal capsule [
         <a href="#rid68">
          68
         </a>
         ]. Existing pneumococcal vaccines utilize capsular polysaccharides as antigens. Vaccines cannot include all serotypes, replacement strains appear, and pneumococci readily acquire deoxyribonucleic acid (DNA) from other microorganisms by transformation, giving them the ability to switch capsular serotypes.
        </p>
        <p>
         These facts have led to attempts to develop vaccines based on highly conserved proteins (eg, pneumolysin, histidine triad protein D, surface proteins A [
         <a href="#rid69">
          69
         </a>
         ] and C), some of which are surface expressed and one of which (pneumolysin) contributes substantially to the pathogenesis of pneumococcal disease. Several such vaccines are in development [
         <a href="#rid39">
          39,56,70-73
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1398409563">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110422.html" rel="external">
          "Society guideline links: Pneumococcal vaccination in adults"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/110427.html" rel="external">
          "Society guideline links: Immunizations in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2951503229">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15745.html" rel="external">
          "Patient education: Vaccines for adults (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/15370.html" rel="external">
          "Patient education: What you should know about vaccines (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/4008.html" rel="external">
          "Patient education: Pneumonia prevention in adults (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2778511355">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rationale for vaccination
         </strong>
         − Pneumococcal infections (eg, pneumonia, bacteremia, meningitis) are an important cause of morbidity and mortality in adults, especially among older adults  (
         <a class="graphic graphic_figure graphicRef138890" href="/z/d/graphic/138890.html" rel="external">
          figure 2
         </a>
         ) and those with certain conditions (eg, immunocompromising conditions, asplenia). Vaccines are effective at reducing the morbidity and mortality associated with pneumococcal disease. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Rationale for vaccination'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Types of vaccines
         </strong>
         − Two types of pneumococcal vaccines are approved and have defined indications for use in the United States  (
         <a class="graphic graphic_table graphicRef87568" href="/z/d/graphic/87568.html" rel="external">
          table 1
         </a>
         ) (see
         <a class="local">
          'Vaccine types'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          pneumococcal polysaccharide vaccine
         </a>
         (PPSV23; Pneumovax 23, Pnu-Immune) that includes 23 partially purified capsular polysaccharide antigens  (
         <a class="graphic graphic_table graphicRef77274" href="/z/d/graphic/77274.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Polysaccharide vaccines'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pneumococcal conjugate vaccines (PCV) − 10-valent PCV (
         <a class="drug drug_general" data-topicid="17136" href="/z/d/drug information/17136.html" rel="external">
          PCV10
         </a>
         ; Synflorix), 13-valent PCV (
         <a class="drug drug_general" data-topicid="9906" href="/z/d/drug information/9906.html" rel="external">
          PCV13
         </a>
         ; Prevnar 13), 15-valent PCV (
         <a class="drug drug_general" data-topicid="132100" href="/z/d/drug information/132100.html" rel="external">
          PCV15
         </a>
         ; Vaxneuvance), and 20-valent PCV (
         <a class="drug drug_general" data-topicid="131831" href="/z/d/drug information/131831.html" rel="external">
          PCV20
         </a>
         ; Prevnar 20) contain capsular polysaccharide antigens covalently linked to a nontoxic protein  (
         <a class="graphic graphic_table graphicRef77274" href="/z/d/graphic/77274.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Conjugate vaccines'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications for pneumococcal vaccination
         </strong>
         − We recommend pneumococcal vaccination for all adults ≥65 years old and adults &lt;65 years old who are at risk for pneumococcal infection or severe complications from pneumococcal infection  (
         <a class="graphic graphic_table graphicRef86782" href="/z/d/graphic/86782.html" rel="external">
          table 3
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Risk factors include immunocompromising conditions (eg, immunosuppressive drugs), chronic predisposing conditions (eg, chronic lung disease, tobacco use), increased risk of meningitis (eg, cerebrospinal fluid [CSF] leak, cochlear implant), functional or anatomic asplenia, and history of invasive pneumococcal disease. (See
         <a class="local">
          'Indications for vaccination'
         </a>
         above and
         <a class="local">
          'Vaccine efficacy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Approach to vaccine selection
         </strong>
         − The United States Centers for Disease Control (CDC) and Prevention Advisory Committee of Immunization Practices (ACIP) recommends administration of
         <a class="drug drug_general" data-topicid="131831" href="/z/d/drug information/131831.html" rel="external">
          PCV20
         </a>
         alone or
         <a class="drug drug_general" data-topicid="132100" href="/z/d/drug information/132100.html" rel="external">
          PCV15
         </a>
         in series with
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          PPSV23
         </a>
         for all patients with an indication for pneumococcal vaccination  (
         <a class="graphic graphic_table graphicRef86782" href="/z/d/graphic/86782.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For immunocompetent adults without increased risk for meningitis, we suggest
         <a class="drug drug_general" data-topicid="131831" href="/z/d/drug information/131831.html" rel="external">
          PCV20
         </a>
         rather than other pneumococcal vaccines (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). If PCV20 is unavailable,
         <a class="drug drug_general" data-topicid="132100" href="/z/d/drug information/132100.html" rel="external">
          PCV15
         </a>
         followed by
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          PPSV23
         </a>
         one year later is an alternative. Both approaches effectively protect against a high proportion of clinically relevant pneumococcal serotypes but a single-vaccine dose with PCV20 ensures adherence and is less costly. (See
         <a class="local">
          'Approach to healthy older adults and those with predisposing medical conditions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For immunocompromised individuals and those at increased risk of meningitis (eg, cochlear implants, CSF leak), the approach differs among UpToDate experts: the authors favor
         <a class="drug drug_general" data-topicid="131831" href="/z/d/drug information/131831.html" rel="external">
          PCV20
         </a>
         followed by
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          PPSV23
         </a>
         ≥8 weeks later to provide protection against serotypes present in PPSV23 that are absent from PCV20  (
         <a class="graphic graphic_figure graphicRef138710" href="/z/d/graphic/138710.html" rel="external">
          figure 3
         </a>
         ). If PCV20 is unavailable,
         <a class="drug drug_general" data-topicid="132100" href="/z/d/drug information/132100.html" rel="external">
          PCV15
         </a>
         followed by PPSV23 is an alternative. The ACIP and the section editor of this topic use the same approach as in immunocompetent patients. (See
         <a class="local">
          'Approach to individuals at highest risk of pneumococcal disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For recipients of older pneumococcal vaccines (eg,
         <a class="drug drug_general" data-topicid="17136" href="/z/d/drug information/17136.html" rel="external">
          PCV10
         </a>
         ,
         <a class="drug drug_general" data-topicid="9906" href="/z/d/drug information/9906.html" rel="external">
          PCV13
         </a>
         ,
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          PPSV23
         </a>
         ), a suggested approach is outlined in the following tables based on age  (
         <a class="graphic graphic_table graphicRef143140" href="/z/d/graphic/143140.html" rel="external">
          table 4
         </a>
         and
         <a class="graphic graphic_table graphicRef143139" href="/z/d/graphic/143139.html" rel="external">
          table 5
         </a>
         ). (See
         <a class="local">
          'Approach to recipients of prior pneumococcal vaccines'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Revaccination
         </strong>
         − The approach to revaccination varies among experts and clinical practice guidelines. The authors of this topic revaccinate all patients who receive
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          PPSV23
         </a>
         as part of their vaccine series (eg,
         <a class="drug drug_general" data-topicid="17136" href="/z/d/drug information/17136.html" rel="external">
          PCV10
         </a>
         /13 and PPSV23,
         <a class="drug drug_general" data-topicid="132100" href="/z/d/drug information/132100.html" rel="external">
          PCV15
         </a>
         and PPSV23, or
         <a class="drug drug_general" data-topicid="131831" href="/z/d/drug information/131831.html" rel="external">
          PCV20
         </a>
         and PPSV23) with PPSV23 every 5 to 10 years. While this differs from the CDC ACIP recommendation, the authors believe the potential benefit of repeat revaccination with PPSV23 every 5 to 10 years greatly outweighs the risks. (See
         <a class="local">
          'Revaccination'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         − Injection site reactions (tenderness, redness, swelling at site) are the most common adverse effects associated with pneumococcal vaccination in adults and are typically mild. Most are self-limited and resolve within a few days of vaccination. Warm compresses and nonsteroidal anti-inflammatory drugs can help with symptom relief. (See
         <a class="local">
          'Adverse effects'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contraindications
         </strong>
         − Vaccination is contraindicated for patients who have a history of a severe allergic reactions (eg, anaphylaxis) to either pneumococcal vaccine or any of its components (eg, diphtheria toxoid for PCV). (See
         <a class="local">
          'Contraindications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3124796440">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Elaine Tuomanen, MD and Patricia Hibberd, MD, PhD who contributed to earlier versions of this topic review.
        </p>
        <p>
         UpToDate also gratefully acknowledges John G Bartlett, MD (deceased), who contributed on earlier versions of this topic review and was a founding Editor-in-Chief for UpToDate in Infectious Diseases.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:109.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. 2018. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae, 2018. https://www.cdc.gov/abcs/reports-findings/survreports/spneu18.pdf (Accessed on February 03, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Subesinghe S, Bechman K, Rutherford AI, et al. A Systematic Review and Metaanalysis of Antirheumatic Drugs and Vaccine Immunogenicity in Rheumatoid Arthritis. J Rheumatol 2018; 45:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forstner C, Plefka S, Tobudic S, et al. Effectiveness and immunogenicity of pneumococcal vaccination in splenectomized and functionally asplenic patients. Vaccine 2012; 30:5449.
          </a>
         </li>
         <li class="breakAll">
          Miwako Kobayashi. Considerations for Age-Based and Risk-Based Use of PCV15 and PCV20 among U.S. Adults and Proposed Policy Options. United States Centers for Disease Control and Prevention Advisory Committee for Immunization Practices meeting, October 20, 2021.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Musher DM, Rodriguez-Barradas MB. Why the recent ACIP recommendations regarding conjugate pneumococcal vaccine in adults may be irrelevant. Hum Vaccin Immunother 2016; 12:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macintyre CR, Ridda I, Gao Z, et al. A randomized clinical trial of the immunogenicity of 7-valent pneumococcal conjugate vaccine compared to 23-valent polysaccharide vaccine in frail, hospitalized elderly. PLoS One 2014; 9:e94578.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mt-Isa S, Abderhalden LA, Musey L, Weiss T. Matching-adjusted indirect comparison of pneumococcal vaccines V114 and PCV20. Expert Rev Vaccines 2022; 21:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohapi L, Pinedo Y, Osiyemi O, et al. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV. AIDS 2022; 36:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Varghese J, Chochua S, Tran T, et al. Multistate population and whole genome sequence-based strain surveillance of invasive pneumococci recovered in the USA during 2017. Clin Microbiol Infect 2020; 26:512.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kobayashi M, Pilishvili T, Farrar JL, et al. Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023. MMWR Recomm Rep 2023; 72:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325:1453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Musher DM, Manoff SB, McFetridge RD, et al. Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults. Hum Vaccin 2011; 7:919.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Musher DM, Manof SB, Liss C, et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis 2010; 201:516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson LA, Gurtman A, van Cleeff M, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013; 31:3577.
          </a>
         </li>
         <li class="breakAll">
          Pneumovax 23 (pneumococcal vaccine polyvalent) sterile, liquid vaccine for intramuscular or subcutaneous injection, prescribing information. http://www.merck.com/product/usa/pi_circulars/p/pneumovax_23/pneumovax_pi.pdf (Accessed on October 24, 2013).
         </li>
         <li class="breakAll">
          VAXNEUVANCE. Package insert. Silver Spring, MD: Food and Drug Administration; 2021. https://www.fda.gov/media/150819/download (Accessed on January 28, 2022).
         </li>
         <li class="breakAll">
          PREVNAR 20. Package insert. Silver Spring, MD: Food and Drug Administration; 2021. https://www.fda.gov/vaccines-blood-biologics/vaccines/prevnar-20 (Accessed on January 28, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Honkanen PO, Keistinen T, Kivelä SL. Reactions following administration of influenza vaccine alone or with pneumococcal vaccine to the elderly. Arch Intern Med 1996; 156:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fitz-Patrick D, Young M, Yacisin K, et al. Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults ≥65 years old. Vaccine 2023; 41:4190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shoar S, Musher DM. Etiology of community-acquired pneumonia in adults: a systematic review. Pneumonia (Nathan) 2020; 12:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           GBD 2016 Lower Respiratory Infections Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis 2018; 18:1191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Musher DM, Johnson B Jr, Watson DA. Quantitative relationship between anticapsular antibody measured by enzyme-linked immunosorbent assay or radioimmunoassay and protection of mice against challenge with Streptococcus pneumoniae serotype 4. Infect Immun 1990; 58:3871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romero-Steiner S, Musher DM, Cetron MS, et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis 1999; 29:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ridda I, Macintyre CR, Lindley R, et al. Immunological responses to pneumococcal vaccine in frail older people. Vaccine 2009; 27:1628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Svensson T, Kättström M, Hammarlund Y, et al. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group. Vaccine 2018; 36:3701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Platt HL, Cardona JF, Haranaka M, et al. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE). Vaccine 2022; 40:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hammitt LL, Quinn D, Janczewska E, et al. Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY). Open Forum Infect Dis 2022; 9:ofab605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Essink B, Sabharwal C, Cannon K, et al. Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years. Clin Infect Dis 2022; 75:390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hurley D, Griffin C, Young M, et al. Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age. Clin Infect Dis 2021; 73:e1489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bolan G, Broome CV, Facklam RR, et al. Pneumococcal vaccine efficacy in selected populations in the United States. Ann Intern Med 1986; 104:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sims RV, Steinmann WC, McConville JH, et al. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med 1988; 108:653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farr BM, Johnston BL, Cobb DK, et al. Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study. Arch Intern Med 1995; 155:2336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348:1747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Austrian R, Douglas RM, Schiffman G, et al. Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physicians 1976; 89:184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bentley DW, Ha K, Mamot K, et al. Pneumococcal vaccine in the institutionalized elderly: design of a nonrandomized trial and preliminary results. Rev Infect Dis 1981; 3 Suppl:S71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maruyama T, Taguchi O, Niederman MS, et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ 2010; 340:c1004.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013; :CD000422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Musher DM. How effective is vaccination in preventing pneumococcal disease? Infect Dis Clin North Am 2013; 27:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Musher DM, Rueda-Jaimes AM, Graviss EA, Rodriguez-Barradas MC. Effect of pneumococcal vaccination: a comparison of vaccination rates in patients with bacteremic and nonbacteremic pneumococcal pneumonia. Clin Infect Dis 2006; 43:1004.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaillat J, Zmirou D, Mallaret MR, et al. [Clinical trial of an antipneumococcal vaccine in elderly subjects living in institutions]. Rev Epidemiol Sante Publique 1985; 33:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson LA, Janoff EN. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin Infect Dis 2008; 47:1328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huss A, Scott P, Stuck AE, et al. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009; 180:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koivula I, Stén M, Leinonen M, Mäkelä PH. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med 1997; 103:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ortqvist A, Hedlund J, Burman LA, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet 1998; 351:399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simberkoff MS, Cross AP, Al-Ibrahim M, et al. Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 315:1318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           French N, Nakiyingi J, Carpenter LM, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000; 355:2106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Djennad A, Ramsay ME, Pebody R, et al. Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine and Changes in Invasive Pneumococcal Disease Incidence from 2000 to 2017 in Those Aged 65 and Over in England and Wales. EClinicalMedicine 2018; 6:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shimbashi R, Suzuki M, Chang B, et al. Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013-2017. Emerg Infect Dis 2020; 26:2378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Su WJ, Chuang PH, Chang LY, et al. Application of the screening and indirect cohort methods to evaluate the effectiveness of pneumococcal vaccination program in adults 75 years and older in Taiwan. BMC Infect Dis 2021; 21:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McLaughlin JM, Jiang Q, Isturiz RE, et al. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design. Clin Infect Dis 2018; 67:1498.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawrence H, Pick H, Baskaran V, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study. PLoS Med 2020; 17:e1003326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372:1114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010; 362:812.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Isturiz R, Grant L, Gray S, et al. Expanded Analysis of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-acquired Pneumonia in Hospitalized US Adults. Clin Infect Dis 2021; 73:1216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Musher DM. Editorial commentary: should 13-valent protein-conjugate pneumococcal vaccine be used routinely in adults? Clin Infect Dis 2012; 55:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vadlamudi NK, Chen A, Marra F. Impact of the 13-Valent Pneumococcal Conjugate Vaccine Among Adults: A Systematic Review and Meta-analysis. Clin Infect Dis 2019; 69:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griffin MR, Zhu Y, Moore MR, et al. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med 2013; 369:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bigogo GM, Audi A, Auko J, et al. Indirect Effects of 10-Valent Pneumococcal Conjugate Vaccine Against Adult Pneumococcal Pneumonia in Rural Western Kenya. Clin Infect Dis 2019; 69:2177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmed SS, Pondo T, Xing W, et al. Early Impact of 13-Valent Pneumococcal Conjugate Vaccine Use on Invasive Pneumococcal Disease Among Adults With and Without Underlying Medical Conditions-United States. Clin Infect Dis 2020; 70:2484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Musher DM. Should Committees That Write Guidelines and Recommendations Publish Dissenting Opinions? Mayo Clin Proc 2016; 91:634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Musher DM, Sampath R, Rodriguez-Barradas MC. The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence? Clin Infect Dis 2011; 52:633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan SL, Barson WJ, Lin PL, et al. Serotype 19A Is the most common serotype causing invasive pneumococcal infections in children. Pediatrics 2010; 125:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Miguel S, Domenech M, González-Camacho F, et al. Nationwide Trends of Invasive Pneumococcal Disease in Spain From 2009 Through 2019 in Children and Adults During the Pneumococcal Conjugate Vaccine Era. Clin Infect Dis 2021; 73:e3778.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bajema KL, Gierke R, Farley MM, et al. Impact of Pneumococcal Conjugate Vaccines on Antibiotic-Nonsusceptible Invasive Pneumococcal Disease in the United States. J Infect Dis 2022; 226:342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Browall S, Norman M, Tångrot J, et al. Intraclonal variations among Streptococcus pneumoniae isolates influence the likelihood of invasive disease in children. J Infect Dis 2014; 209:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lane JR, Tata M, Briles DE, Orihuela CJ. A Jack of All Trades: The Role of Pneumococcal Surface Protein A in the Pathogenesis of Streptococcus pneumoniae. Front Cell Infect Microbiol 2022; 12:826264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moffitt KL, Malley R. Next generation pneumococcal vaccines. Curr Opin Immunol 2011; 23:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan WY, Entwisle C, Ercoli G, et al. Corrected and Republished from: "A Novel, Multiple-Antigen Pneumococcal Vaccine Protects against Lethal Streptococcus pneumoniae Challenge". Infect Immun 2022; 90:e0084618a.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplonek P, Yao L, Reppe K, et al. A semisynthetic glycoconjugate provides expanded cross-serotype protection against Streptococcus pneumoniae. Vaccine 2022; 40:1038.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thanawastien A, Joyce KE, Cartee RT, et al. Preclinical in vitro and in vivo profile of a highly-attenuated, broadly efficacious pneumolysin genetic toxoid. Vaccine 2021; 39:1652.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7021 Version 106.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35085226" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35085226" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29545454" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : A Systematic Review and Metaanalysis of Antirheumatic Drugs and Vaccine Immunogenicity in Rheumatoid Arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22749594" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Effectiveness and immunogenicity of pneumococcal vaccination in splenectomized and functionally asplenic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22749594" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Effectiveness and immunogenicity of pneumococcal vaccination in splenectomized and functionally asplenic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26606172" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Why the recent ACIP recommendations regarding conjugate pneumococcal vaccine in adults may be irrelevant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24760002" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : A randomized clinical trial of the immunogenicity of 7-valent pneumococcal conjugate vaccine compared to 23-valent polysaccharide vaccine in frail, hospitalized elderly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34672224" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Matching-adjusted indirect comparison of pneumococcal vaccines V114 and PCV20.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34750291" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31536818" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Multistate population and whole genome sequence-based strain surveillance of invasive pneumococci recovered in the USA during 2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37669242" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Pneumococcal Vaccine for Adults Aged≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1944423" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21860256" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20092407" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23688526" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23688526" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23688526" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23688526" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8546555" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Reactions following administration of influenza vaccine alone or with pneumococcal vaccine to the elderly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37244809" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults ≥65 years old.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33024653" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Etiology of community-acquired pneumonia in adults: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30243584" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2254015" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Quantitative relationship between anticapsular antibody measured by enzyme-linked immunosorbent assay or radioimmunoassay and protection of mice against challenge with Streptococcus pneumoniae serotype 4.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10476727" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19100304" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Immunological responses to pneumococcal vaccine in frail older people.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29748028" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34507861" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35146039" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34940806" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged≥18 Years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32716500" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3940476" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Pneumococcal vaccine efficacy in selected populations in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3358567" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : The clinical effectiveness of pneumococcal vaccine in the elderly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7487259" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12724480" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Effectiveness of pneumococcal polysaccharide vaccine in older adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14433" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Prevention of pneumococcal pneumonia by vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7280449" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Pneumococcal vaccine in the institutionalized elderly: design of a nonrandomized trial and preliminary results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20211953" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23440780" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Vaccines for preventing pneumococcal infection in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23398877" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : How effective is vaccination in preventing pneumococcal disease?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16983612" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Effect of pneumococcal vaccination: a comparison of vaccination rates in patients with bacteremic and nonbacteremic pneumococcal pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3914014" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : [Clinical trial of an antipneumococcal vaccine in elderly subjects living in institutions].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18844484" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Pneumococcal vaccination of elderly adults: new paradigms for protection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19124790" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Efficacy of pneumococcal vaccination in adults: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9382120" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9482293" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3534568" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10902624" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31193709" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine and Changes in Invasive Pneumococcal Disease Incidence from 2000 to 2017 in Those Aged 65 and Over in England and Wales.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32946721" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013-2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33423657" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Application of the screening and indirect cohort methods to evaluate the effectiveness of pneumococcal vaccination program in adults 75 years and older in Taiwan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29790925" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33095759" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25785969" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20200385" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33982098" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Expanded Analysis of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-acquired Pneumonia in Hospitalized US Adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22495544" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Editorial commentary: should 13-valent protein-conjugate pneumococcal vaccine be used routinely in adults?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10749457" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30312379" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Impact of the 13-Valent Pneumococcal Conjugate Vaccine Among Adults: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19947881" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23841730" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30785189" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Indirect Effects of 10-Valent Pneumococcal Conjugate Vaccine Against Adult Pneumococcal Pneumonia in Rural Western Kenya.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31402387" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Early Impact of 13-Valent Pneumococcal Conjugate Vaccine Use on Invasive Pneumococcal Disease Among Adults With and Without Underlying Medical Conditions-United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27061767" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Should Committees That Write Guidelines and Recommendations Publish Dissenting Opinions?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21292668" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20176669" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Serotype 19A Is the most common serotype causing invasive pneumococcal infections in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32990303" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Nationwide Trends of Invasive Pneumococcal Disease in Spain From 2009 Through 2019 in Children and Adults During the Pneumococcal Conjugate Vaccine Era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35481950" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Impact of Pneumococcal Conjugate Vaccines on Antibiotic-Nonsusceptible Invasive Pneumococcal Disease in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24009156" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Intraclonal variations among Streptococcus pneumoniae isolates influence the likelihood of invasive disease in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35186799" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : A Jack of All Trades: The Role of Pneumococcal Surface Protein A in the Pathogenesis of Streptococcus pneumoniae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21514128" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Next generation pneumococcal vaccines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35076289" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Corrected and Republished from: "A Novel, Multiple-Antigen Pneumococcal Vaccine Protects against Lethal Streptococcus pneumoniae Challenge".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35033388" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : A semisynthetic glycoconjugate provides expanded cross-serotype protection against Streptococcus pneumoniae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32532546" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Preclinical in vitro and in vivo profile of a highly-attenuated, broadly efficacious pneumolysin genetic toxoid.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
